Organon & Co. OGN
We take great care to ensure that the data presented and summarized in this overview for Organon & Co. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OGN
View all-
Black Rock Inc. New York, NY33.5MShares$731 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.8MShares$671 Million0.01% of portfolio
-
Massachusetts Financial Services CO Boston, MA10.2MShares$221 Million0.06% of portfolio
-
State Street Corp Boston, MA9.3MShares$203 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.18MShares$135 Million0.02% of portfolio
-
Slate Path Capital LP New York, NY5.15MShares$112 Million1.94% of portfolio
-
Morgan Stanley New York, NY5.04MShares$110 Million0.01% of portfolio
-
Harry Burn Sound Shore Management Inc5.02MShares$110 Million3.02% of portfolio
-
Lsv Asset Management Chicago, IL4.49MShares$97.9 Million0.17% of portfolio
-
Nordea Investment Management Ab Stockholm, V73.97MShares$86.6 Million0.09% of portfolio
Latest Institutional Activity in OGN
Top Purchases
Top Sells
About OGN
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Insider Transactions at OGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 04
2024
|
Rachel A Stahler Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,045
-2.12%
|
$19,855
$19.61 P/Share
|
May 04
2024
|
Rachel A Stahler Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,049
+5.83%
|
-
|
May 04
2024
|
Matthew M Walsh Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,093
-4.43%
|
$77,767
$19.61 P/Share
|
May 04
2024
|
Matthew M Walsh Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,310
+8.25%
|
-
|
May 04
2024
|
Kathryn Di Marco Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
428
-2.0%
|
$8,132
$19.61 P/Share
|
May 04
2024
|
Kathryn Di Marco Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,248
+5.51%
|
-
|
May 04
2024
|
Aaron Falcione Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
949
-3.03%
|
$18,031
$19.6 P/Share
|
May 04
2024
|
Aaron Falcione Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,770
+8.12%
|
-
|
May 04
2024
|
Kirke Weaver Gen. Counsel & Corp. Secy. |
SELL
Payment of exercise price or tax liability
|
Direct |
356
-1.21%
|
$6,764
$19.61 P/Share
|
May 04
2024
|
Kirke Weaver Gen. Counsel & Corp. Secy. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,248
+4.06%
|
-
|
May 04
2024
|
Kevin Ali Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,256
-8.31%
|
$232,864
$19.61 P/Share
|
May 04
2024
|
Kevin Ali Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,161
+13.06%
|
-
|
May 04
2024
|
Susanne Fiedler Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,589
-3.04%
|
$30,191
$19.61 P/Share
|
May 04
2024
|
Susanne Fiedler Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,989
+8.72%
|
-
|
May 04
2024
|
Vittorio Nisita Head of Global Business Svcs |
SELL
Payment of exercise price or tax liability
|
Direct |
712
-3.08%
|
$13,528
$19.61 P/Share
|
May 04
2024
|
Vittorio Nisita Head of Global Business Svcs |
BUY
Exercise of conversion of derivative security
|
Direct |
2,078
+8.25%
|
-
|
May 04
2024
|
Joseph T. Morrissey Jr. Head of Manufacturing |
SELL
Payment of exercise price or tax liability
|
Direct |
1,568
-3.7%
|
$29,792
$19.61 P/Share
|
May 04
2024
|
Joseph T. Morrissey Jr. Head of Manufacturing |
BUY
Exercise of conversion of derivative security
|
Direct |
3,604
+7.83%
|
-
|
Mar 31
2024
|
Kathryn Di Marco Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
4,384
-10.9%
|
$78,912
$18.8 P/Share
|
Mar 31
2024
|
Kathryn Di Marco Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
12,797
+24.03%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 10.1K shares |
---|---|
Exercise of conversion of derivative security | 432K shares |
Open market or private purchase | 2.72K shares |
Payment of exercise price or tax liability | 185K shares |
---|